Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2018-01-18 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
北京中同华资产评估有限公司关于上海证券交易所《关于对中源协和发行股份购买资产并募集配套资金暨关联交易报告书（草案）信息披露的问询函》之回复
Regulatory Filings Classification · 95% confidence The document is a detailed response from an asset appraisal company to an inquiry letter from the Shanghai Stock Exchange regarding a draft report on a share issuance for asset purchase and related party transaction. It includes quantitative analysis of financial impacts, explanations about the rationale behind earnings forecasts, and opinions from financial advisors and appraisers. The content focuses on financial evaluation, asset purchase, and related party transaction disclosures rather than being a full annual or interim report, earnings release, or management discussion. It is not a simple announcement or certification but a substantive reply to regulatory inquiries about a specific transaction and its financial implications. This fits the category of Regulatory Filings (RNS) as it is a regulatory response document that does not constitute a full financial report or other specific filing type.
2018-01-18 Chinese
发行股份购买资产并募集配套资金暨关联交易报告书（草案）（修订稿）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed report concerning a major asset restructuring involving issuance of shares to purchase assets and raising supporting funds, including related party transactions. It includes transaction details, pricing, shareholder structure changes, profit forecasts, compensation arrangements, risk disclosures, and regulatory approval requirements. The content is consistent with a major asset restructuring report, which is a form of capital/financing update related to issuance of shares and fundraising activities. It is not a full annual or interim financial report, nor a simple announcement or certification. The document length and detail confirm it is the report itself, not just an announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2018-01-18 Chinese
华英证券有限责任公司关于中源协和细胞基因工程股份有限公司发行股份及支付现金购买资产并募集配套资金限售股份上市流通的核查意见
Share Issue/Capital Change Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion regarding the listing and circulation of restricted shares following a non-public issuance of shares by the company. It references regulatory approvals, share lock-up periods, shareholding changes, and compliance with relevant laws and stock exchange rules. The document does not present financial statements or earnings data but focuses on the verification and compliance of share issuance and restricted share circulation. This type of document is typically a regulatory announcement related to capital changes and share issuance, specifically about restricted shares becoming tradable. Given the content and the focus on share issuance, lock-up, and listing of restricted shares, the most appropriate classification is Share Issue/Capital Change (SHA). The document length is 3244 characters, which is not extremely short, and it contains substantive information about share issuance and capital structure changes, not just an announcement of a report or certification. Therefore, it is not RPA or RNS.
2018-01-16 Chinese
非公开发行限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the listing and circulation of restricted shares from a non-public issuance by the company 中源协和细胞基因工程股份有限公司. It details the number of shares becoming tradable, the lock-up periods, shareholder commitments, and changes in share capital. It references regulatory approvals and audit opinions but does not contain financial statements or detailed financial performance data. The document is relatively short (3300 characters) and serves as an official notice about share circulation rather than a full financial report or earnings release. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements about new share issues, stock unlockings, or capital changes.
2018-01-16 Chinese
关于收到上海证券交易所问询函的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding receipt of an inquiry letter from the Shanghai Stock Exchange about a draft report on issuance of shares to purchase assets and related party transactions. The content focuses on questions and requests for further disclosure and explanations related to the draft report, including financial data, valuation, and transaction details. It is not the report itself but an official regulatory communication about the inquiry and the company's planned response. The document length is short (2554 characters) and it does not contain actual financial statements or substantive financial data but rather a regulatory inquiry and company announcement. Therefore, it fits best under Regulatory Filings (RNS) as a regulatory announcement and response to an inquiry letter, not as the actual asset purchase report or financial report.
2018-01-15 Chinese
关于控股股东部分股权解除质押及再质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the pledge and release of shares by the controlling shareholder of the company. It details the number of shares pledged, released, and the purpose of the pledge. There is no financial report, earnings data, or management discussion. The content is about share pledge status and related shareholder information, which fits the category of Major Shareholding Notification (MRQ). The document length is short and it is not a report publication or certification. Therefore, the appropriate classification is MRQ.
2018-01-10 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.